عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

Entrepreneurs, Creatives Compete to Build 'Global Talents Platform' in Saudi Arabia

Mawhiba logo.
Mawhiba logo.
TT
TT

Entrepreneurs, Creatives Compete to Build 'Global Talents Platform' in Saudi Arabia

Mawhiba logo.
Mawhiba logo.

Around 100 talented young men and women, and entrepreneurs from 30 countries will gather in Jeddah to compete for building a global platform for talents. Launching from Saudi Arabia, the platform aims to grow a global community of creatives, and establish a future trend that inspires dreamers around the world.

Under the patronage of the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, the King Abdulaziz and His Companions Foundation for Giftedness and Creativity (Mawhiba), organizes the second edition of the Global Conference for Giftedness and Creativity 2022, on December 10.

It brings together the young and creative minds from around the world in a “Journey Toward the New Future.”

Mawhiba Secretary-General Amal Al-Hazzaa said that “the second edition of the conference aims to anticipate the future, profiting from the leading position of the Kingdom in human development and support of talented youth.”

The talented participants were selected from 30 countries around the world to work on forward-thinking solutions that address global challenges, improve people’s lives, inspire and empower the talented youth worldwide to shape a new future, and create a global platform to develop and manage expertise, talents.

The unique event brings together talented and creative youth from around the world to help build a platform that provides solutions for the challenges of sustainable development.

When built, this platform will serve as a pioneering model of collective thinking that empowers the young generation to build the new world.

Over 100 talented young men and women from around the world will partake in the conference. Some are still students, others have already got their degrees from the best 50 universities in the world. The talents will be overseen by experts specialized in creativity and technology, and will work in groups divided based on talents and specialties.

The conference hosts national and international inspiring speakers, CEOs, and pioneers from different sectors. It also features workshops, discussion panels, and talent shows that target policy and decision makers, entrepreneurs, and international experts.

The Global Conference for Giftedness and Creativity 2022 includes an “idea-thon,” aimed at developing a global platform that empowers talents from around the world to find solutions for the different challenges that face the communities of the future.

The to-be-developed platform aims to attract and develop talents, and produce sustainable innovative solutions to the future global challenges.

The Global Conference for Giftedness and Creativity, organized by Mawiba, was held for the first time in 2020 on the sidelines of the G20 Summit hosted by Riyadh at the time. Back then, the Custodian of the Two Holy Mosques directed to hold the conference every two years to help create future horizons, emphasize the potentials of the talented youth in the face of global challenges, create efficient solutions, and expand the scope of the global cooperation through active partnerships to grow a human capital capable of facing the developments and challenges.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”